Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 2c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.41), $0.02 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $20 thousand versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Nvidia and Broadcom earnings: TD Cowen says earnings won’t settle big questions
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c